Evaluation of a 3D Functional Metabolic Imaging and Risk Assessment System in Classifying Women for Likelihood of Breast Cancer

Breast Cancer Clinical Trial

Official title:

Evaluation of a Three Dimensional Functional Metabolic Imaging and Risk Assessment System in Classifying Women for Likelihood of Breast Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03296683
• Other study ID #: 960-CLP-ITL_RI8 _ITS1
• Status: Recruiting
• Phase: N/A
• Start date: May 23, 2017
• Est. completion date: September 2021

Study information

• Verified date: June 2018
• Source: Real Imaging Ltd.
• Contact: David Izhaky
• Phone: +972-3-972-0602
• Email: david[@]realimaging.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study objective is to evaluate the added value of MIRA technology as an adjunct to mammography in the detection of malignant breast lesions in women with dense breast and/or at elevated risk of breast cancer.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1200
• Est. completion date: September 2021
• Est. primary completion date: September 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 24 Years and older

Eligibility

Inclusion Criteria:

**Calibration Phase:

A.Subjects who are asymptomatic and scheduled to undergo routine screening mammography.

OR

B.Subjects scheduled for image guided needle biopsy as a result of findings obtained during standard of care (mammography, ultrasound and/or MRI)

**Testing Phase:

A. Subjects scheduled to undergo routine screening mammography and at least one of the following :

• Subjects whose most recent (within 3 years) prior mammogram was interpreted as heterogeneously dense (ACR BI-RADS Breast Density 3) or extremely dense (ACR BI-RADS Breast Density 4).

• Subjects whose current 10-year IBIS breast cancer risk is 5% or higher.

EXCLUSION CRITERIA, valid for both calibration and testing phases:

1. Male by birth.

2. Individual is less than 24 years old.

3. Contraindication to bilateral mammography or MRI.

4. Subjects who are unable to read, understand and execute the informed consent procedure.

5. Subjects who have had mammography, ultrasound or MRI examination performed on the day of the study prior to MIRA scan.

6. Subjects who have significant existing breast trauma.

7. Subjects who have undergone lumpectomy/mastectomy.

8. Subjects who have undergone breast reduction or breast augmentation.

9. Subjects who have undergone any other type of breast surgery.

10. Subjects who have large breast scar / Breast deformation.

11. Subjects who have undergone a breast needle biopsy within the 6 month period prior to their intended enrollment into the study.

12. Subjects who have a temperature > 100° F (37.8C) degrees on the day of the MIRA imaging.

13. Subjects who are pregnant or lactating.

14. Subjects who have had placement of an internal breast marker.

15. Subjects with known Raynaud's Disease.

16. Subjects that are claustrophobic or have physical limitations that do allow them to sit in the system chair for the required imaging session.

17. Subjects with implanted pacemaker/defibrillator, implanted venous access device (portacath) or other implanted devices.

18. Subjects with a BI-RADS category 6 (e.g. for which mammogram was performed for the purpose of planning cancer therapy).

19. Subjects affected with epilepsy.

20. Subjects who participated in the Calibration Phase will not be able to participate in the Testing Phase.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Device:
• MIRA device imaging
MIRA Device imaging for adjunctive detection of breast cancer

Locations

Country	Name	City	State
Italy	Policlinico San Donato	San Donato Milanese

Sponsors (1)

Lead Sponsor	Collaborator
Real Imaging Ltd.

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Increase in incremental cancer detection rate	Statistically significant increase of 30% or more in incremental cancer detection rate	24 months